Alkylating Agents, the Road Less Traversed, Changing Anticancer Therapy.

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Cancer presents a significant global health challenge, with increasing incidence and mortality rates.
• Nitrogen mustard, an alkylating agent, revolutionized cancer chemotherapy upon its 1942 discovery.
• Alkylating agents function by cross-linking DNA strands, inhibiting replication and inducing cancer cell death.

Purpose of the Study:

• To review the diverse applications of alkylating agents in cancer therapy.
• To examine the Structure-Activity Relationship (SAR) of various alkylating agent classes.
• To provide insights for developing novel alkylating agents with improved efficacy and specificity.

Main Methods:

• Literature review of alkylating agents in cancer chemotherapy.
• Analysis of molecular mechanisms of DNA alkylation.
• Examination of historical and recent structural modifications of alkylating agents.

Main Results:

• Alkylating agents were among the first effective non-hormonal anti-cancer drugs.
• Nitrogen mustard's reactivity leads to DNA damage but also significant side effects.
• Decades of research have focused on enhancing efficacy and tumor-targeting of these agents.

Conclusions:

• Alkylating agents remain vital in treating leukemia and lymphoma.
• Understanding SAR is key to overcoming limitations like cytotoxicity and poor bioavailability.
• Future research aims to synthesize next-generation alkylating agents with enhanced tumor specificity and therapeutic windows.